Deerfield Management Company, L.P. (Series C) Vigil Neuroscience, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.68 - $3.63 $517,808 - $701,359	-193,212 Reduced 16.46%	980,311 $3.34 Million
Q4 2023 Feb 14, 2024	SELL	$2.97 - $8.6 $1.94 Million - $5.62 Million	-653,877 Reduced 35.78%	1,173,523 $3.97 Million
Q3 2023 Nov 14, 2023	SELL	$4.8 - $9.92 $1.08 Million - $2.23 Million	-224,610 Reduced 10.95%	1,827,400 $9.85 Million
Q4 2022 Feb 14, 2023	SELL	$8.74 - $15.99 $24,332 - $44,516	-2,784 Reduced 0.14%	2,052,010 $25.7 Million
Q3 2022 Nov 14, 2022	BUY	$2.37 - $9.61 $4.87 Million - $19.7 Million	2,054,794 New	2,054,794 $18 Million

Others Institutions Holding VIGL

# of Institutions

Shares Held

28.2M

Call Options Held

Put Options Held

View Full List

About Vigil Neuroscience, Inc.

Ticker VIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,268,600
Market Cap $62.2M
Description
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed...

More about VIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account